About Trilogy International Partners (TSE:TRL)
Trilogy International Partners Inc, formerly Alignvest Acquisition Corporation, is a Canada-based wireless telecommunications operator. The Company provides wireless communications services through its subsidiaries in New Zealand and Bolivia. Its subsidiaries include Viva and 2degrees. Viva provides voice and a range of data services to its mobile customers over its third generation (3G)-enabled global system for mobile communications (GSM) and fourth generation (4G) long term evolution (LTE) networks. Viva's service offerings include mobile wallet, local and international electronic top-up services, fixed telephony services, and postpaid and prepaid payment options. 2degrees is a full-service communications provider with a fixed broadband solution. 2degrees' services offerings include Voice, data and short messaging service (SMS) over second generation (2G), 3G and 4G; wireless and fixed broadband services; postpaid carryover minutes, and international roaming in over 130 countries.
Industry, Sector and Symbol:
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Sector: Healthcare
- Symbol: TSE:TRL
- Previous Symbol: TSE:AQX.A
- CUSIP: N/A
- Web: www.trilogy-international.com
- Trailing EPS: C($140.00)
- Net Margins: -5.58%
- Return on Assets: -5.37%
- Outstanding Shares: 44,252,000
Frequently Asked Questions for Trilogy International Partners (TSE:TRL)
What is Trilogy International Partners' stock symbol?
Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL."
How often does Trilogy International Partners pay dividends? What is the dividend yield for Trilogy International Partners?
Trilogy International Partners announced a quarterly dividend on Wednesday, April 26th. Shareholders of record on Friday, May 12th will be given a dividend of 0.02 per share on Friday, May 12th. This represents a $0.08 annualized dividend and a yield of 1.40%. The ex-dividend date of this dividend is Wednesday, April 26th. View Trilogy International Partners' Dividend History.
Where is Trilogy International Partners' stock going? Where will Trilogy International Partners' stock price be in 2017?
3 brokers have issued 1-year target prices for Trilogy International Partners' stock. Their forecasts range from C$7.00 to C$11.00. On average, they expect Trilogy International Partners' stock price to reach C$9.67 in the next year. View Analyst Ratings for Trilogy International Partners.
Who are some of Trilogy International Partners' key competitors?
Some companies that are related to Trilogy International Partners include SkyePharma PLC (SKP), Medical Facilities Corp (DR), Syneron Medical (ELOS), OrganiGram Holdings (OGI), MannKind Corporation (MNKD), IRIS International (IRIS), ECO Animal Health Group plc (EAH), Horizon Discovery Group plc (HZD), Cambian Group PLC (CMBN), Biotie Therapies Corp (BITI), Sequenom (SQNM), Circassia Pharmaceuticals PLC (CIR), Palomar Medical Technologies (PMTI), Cellular Dynamics International (ICEL), TSO3 (TOS), Mereo BioPharma Group plc (MPH), Allergy Therapeutics plc (AGY) and Athersys (ATHX).
How do I buy Trilogy International Partners stock?
Shares of Trilogy International Partners and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Trilogy International Partners' stock price today?
One share of Trilogy International Partners stock can currently be purchased for approximately C$5.70.
How big of a company is Trilogy International Partners?
Trilogy International Partners has a market capitalization of C$253.71 million.
How can I contact Trilogy International Partners?
Trilogy International Partners' mailing address is 155 108th Ave NE Ste 400, BELLEVUE, WA 98004-8703, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900.
MarketBeat Community Rating for Trilogy International Partners (TSE TRL)MarketBeat's community ratings are surveys of what our community members think about Trilogy International Partners and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Trilogy International Partners (TSE:TRL) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.67)|
|Consensus Price Target: ||C$9.67|
Consensus Price Target History for Trilogy International Partners (TSE:TRL)
Analysts' Ratings History for Trilogy International Partners (TSE:TRL)
(Data available from 11/22/2015 forward)
|11/13/2017||Royal Bank Of Canada||Boost Price Target||Outperform||C$9.00 -> C$11.00|
|11/10/2017||TD Securities||Downgrade||Buy -> Hold||C$9.50 -> C$7.00|
|11/9/2017||Scotiabank||Boost Price Target||Outperform||C$9.50 -> C$11.00|
Earnings History and Estimates Chart for Trilogy International Partners (TSE:TRL)
Earnings History by Quarter for Trilogy International Partners (TSE TRL)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Trilogy International Partners (TSE:TRL)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History by Quarter for Trilogy International Partners (TSE TRL)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Trilogy International Partners (TSE TRL)
Insider Trades by Quarter for Trilogy International Partners (TSE TRL)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/13/2015||Nathan John Bryson||Insider||Buy||4,500||C$0.40||C$1,800.00|
|3/24/2015||Tommaso (Tom) Rossi||Insider||Buy||30,000||C$0.82||C$24,600.00|
Latest Headlines for Trilogy International Partners (TSE TRL)
Financials are not available for this stock.
Trilogy International Partners (TSE TRL) Chart for Wednesday, November, 22, 2017